In view of the potential menace of a terrorism attack with smallpox virus, an intensive search of chemotherapeutic agents active against orthopoxviruses is underway. We comparatively studied the antiviral activity of cidofovir (CDV) and idoxuridine (IUdR) against two vaccinia virus (VV) strains, Bratislava and RIIPD, in cell cultures of chick embryo fibroblasts (CEF). The investigations were carried out according to cytopathic effect (CPE) inhibition assay protocols. To determine the cytotoxicity of the compounds, maximal tolerated concentration (MTC) was calculated in CEF cell monolayers and 50% cell growth inhibitory concentration (CGIC 50 ) was calculated in growing cell cultures. It was found that the antiviral effects were strongly dependent on virus inoculum size. There were no marked differences in the susceptibility to CDV and IUdR between the two VV strains. The individual half maximal inhibitory concentration (IC 50 ) for CDV varied from 7.1-8.5 µ µM at 10/100 virus 50% infectious dose (ID 50 ) to 13.6-26.5 µ µM at 10,000 ID 50 . The CDV selectivity index was also virus dose-dependent with MTC/IC 50 and CGIC 50 /IC 50 values ranging between 37.8-141.4 and 33.3-124.6, respectively. For IUdR, IC 50 ranged from 0.58 to 0.85 µ µM, but the selectivity index for monolayer CEF and growing cell cultures produced substantial different results with MTC/IC 50 and CGIC 50 /IC 50 values between 117.7-172.4 and 20.4-33.3, respectively. The combination effects of CDV and IUdR against VV Bratislava strain in the CPE inhibition test were also determined. The test design of both combination antiviral effect and combined cytotoxicity followed a three-dimensional model. The combined effect of CDV and IUdR on VV replication in monolayer CEF cultures was characterized as a markedly synergistic one. In contrast, CDV and IUdR together reduced cytotoxicity in both monolayer and growing CEF cells.
Smallpox (variola) is among the most dangerous and highly contagious viral infections affecting humans. The last natural case in Somalia has marked the end of a successful WHO campaign for smallpox eradication by vaccination on a worldwide scale (Deria et al., 1972; Fenner et al., 1988) . As a result, the smallpox virus can only be found in laboratories in Atlanta, Georgia, USA and Novosibirsk, Siberia, Russia. Despite smallpox eradication, infections caused by other members of the poxvirus family are also important for human health. The monkeypox virus can infect humans and occasional cases have been reported in Equatorial Africa (Heiner et al., 1998) . Molluscum contagiosum and orf infections occur in immunocompromised patients (Kuhl et al., 2003; Murray, 2004) . In addition, it has been highlighted that people not vaccinated with vaccinia virus (VV) could become the target of a potential terrorist attack with smallpox (Mahy, 2003) . Therefore, there is a need to renew the search of chemotherapeutical agents active against poxviruses.
Poxviruses encode a large number of enzymes including DNA polymerase and thymidine kinase, which are of potential interest as targets for antiviral compounds (Citarella et al., 1972; Kit et al., 1977) . The first compound described in the literature was p-amino-benzaldehyde thiosemicarbazone, which Brownlee and Hamre (1951) established inhibited the replication of VV. Bauer and Sadler (1960) found 1-methyl-1H-indole-2,3-dione-3thiosemicarbazone (methisazone, Marboran ® ) manifested a prophylactic and not a therapeutic effect against smallpox. Later, Borysiewicz et al., (1977) found a comparatively low selectivity ratio value for 1-methyl-1H-indole-2,3-dione-3-thiosemicarbazone based on its marked immunotoxicity. Among compounds showing an anti-poxvirus activity are idoxuridine (IUdR), ribavirin, cidofovir (CDV), interferon and polyacrylic acid (De Clercq, 2001) .
CDV is an acyclic nucleoside phosphonate licensed for the treatment of cytomegalovirus retinitis in AIDS patients. CDV is very effective in vitro against VV, cowpox, monkeypox, camelpox and smallpox viruses (Kern et al., 2002; Smee et al., 2002) ; it has shown to strongly inhibit orthopoxvirus infection in vivo, including cowpox and VV infections in mice (Neyts & De Clercq, 1993; Roy et al., 2003) , and demonstrates a marked activity in mice with respiratory cowpox virus infection when prescribed as a combined treatment with ribavirin (Smee et al., 2000) . More recently, CDV has been approved for the treatment of molluscum contagiosum and orf infections in humans (Silverberg, 2003; McCabe et al., 2003) , and has demonstrated a marked protective effect in variola and monkeypox infection in cynomolgus monkeys (Huggins et al., 2004) .
IUdR was the pioneer antiviral compound used in the treatment of lethal orthopoxvirus infections by systemic administration until smallpox eradication (Loddo, 1963; Neyts et al., 2002) . Investigations on compound activity in vivo and in experimental models of orthopoxvirus infections in mice showed some conflicting results. IUdR demonstrated a marked protective effect versus lethal VV infection (Neyts et al., 2002) , but provided no positive benefit against a lethal cowpox virus infection (Smee & Sidwell, 2004) .
The development of an effective combination of antiviral compounds is considered a promising approach in antiviral chemotherapy and is capable of increasing its efficacy. Several studies have reported the combined effect of antiviral compounds with different mode of action versus VV replication: distamycin A with hyroxyurea, cytosine arabinoside with IUdR and amethopterin plus IUdR (Pancheva-Golovinska, 1975; Surjono et al., 1981) . As studies on the antipoxvirus effects of CDV and IUdR have marked important steps in the development of antipoxvirus chemotherapy, it would be interesting to investigate their combined effect. In this study, we examined the effect of CDV and IUdR on VV replication, in vitro, in chick embryo fibroblasts (CEF) cells. It is expected that the combined application of both drugs, which possess different modes of action, might enhance the inhibition of VV replication. The Bratislava and RIIPD strains of VV were respectively obtained from the Institute of Virology, Bratislava, Slovakia and from the collection of the Stephan Angeloff Institute of Microbiology, Sofia, Bulgaria (originally from the former Research Institute of Infectious and Parasitic Diseases, Sofia, Bulgaria). Both VV strains were cultivated on the chorioallantoic membrane of 11-day-old chick embryos (200 cell culture infective dose 50 [CCID 50 ] /0.2 ml). The embryos were incubated at 37 o C for 5 days. After several passages in the chick embryos, the virus strains underwent two passages in the primary culture of CEF cells. The stock virus infectious titre was 10 7 CCID 50 /ml for both virus strains.
Materials and methods
CEF primary cultures used for virus cultivation were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (Gibco BRL, Paisley, UK), supplemented with 10 mM HEPES buffer (Merck, Darmstadt, Germany) and antibiotics (penicillin 100 IU/ml, streptomycin 100µg/ml) in an incubator (HERA cell 150, Heraeus, Hanau, Germany) at 37 o C in 5% CO 2 .
Cytotoxicity assays
The individual and combined cytotoxicity of CDV and IUdR was assayed in both monolayer and growing CEF cell cultures. The effect of CDV, IUdR or a combination of both compounds was traced microscopically on uninfected cell monolayers (in the stationary growth phase) in 96-well microplates (Costar, Corning, NY, USA). The monolayer cell state and cellular morphology were monitored for signs of cytotoxicity during 48 h and the maximal tolerated concentration (MTC) value was determined. In addition, quantitative assessment of possible cytostatic effect was made by growing uninfected cells in 24-well Costar plates in the presence of the compounds until the control cells (cells without tested compounds in the growth medium) reached stationary growth phase, usually occurring within a 48 h incubation period. The viable cells were then tripsinized and counted. The 50% cell growth inhibitory concentration (CGIC 50 ) value was estimated on the basis of the average cell number counted.
Cytopathic effect (CPE) inhibition assay procedure
Monolayer CEF cells in 96-well plates were inoculated with serial 10-fold virus dilutions ranging from 10 to 10,000 CCID 50 in 0.1 ml per well. Dilutions were carried out in maintenance medium, Dulbecco's modified Eagle's medium (Gibco BRL) supplemented with 2% fetal bovine serum (Gibco BRL) and antibiotics. After 2 h at room temperature for virus adsorption, the test compounds were added separately at different concentrations (in one-half log 10 dilutions in 0.1 ml per well) or together in different combinations (see below). Plates were incubated at 37 o C in CO 2 for 48 h and viral CPE was determined every day by inverted light microscope at ×125 magnification. Compound 50% inhibitory concentration (IC 50 ) value was defined as the lowest concentration reducing virus-induced CPE by 50%. The results were the means of three independent experiments. Some of these experiments were repeated using visually determined CPE, which was confirmed by neutral red dye uptake indicating the visual values obtained (as shown in Table 1 and Table 2 ) were satisfactory quantitative. In this case, the standard neutral red procedure to quantitate the compound antiviral activity and cytotoxicity Smee et al., 2001) was applied. Absorbance values at 540 nm were recorded with a microplate reader (Organon Teknika Reader 530, Salzburg, Austria). Absorbance values are presented as percentages of the untreated controls. The IC 50 values were evaluated by regression analysis of the absorbance means expressed as percentages of untreated and uninfected control values for each compound concentration. The 50% cytotoxic concentrations (CC 50 ) were also calculated by regression analysis.
Antiviral selectivity evaluation
Selectivity of antiviral effect was determined by calculating the two variants of selectivity index (SI) values. The first based on compound tested cytotoxicity on the cell monolayer; MTC divided by IC 50 . The second, based on compound effect on growing cells: CGIC 50 divided by IC 50 .
Combination activity assay
The combined cytotoxicity and CPE-inhibition assay for CDV and IUdR (VV, Bratislava strain) was performed according to the three-dimensional model (Prichard & Shipman, 1990; Nikolaeva and Galabov, 1999) for analysis of drug-drug interactions. A checkerboard design of experiments was made with different concentrations of each compound in each combination. Experiments were done in duplicate with three parallels per sample. The experimental data was evaluated by the MacSynergy TM II program (Prichard et al., 1992) . Theoretical additive interactions were calculated from the dose-response curves for each drug tested individually. The obtained theoretical additive surface was subtracted from the experimentally determined doseresponse surface. The 95% confidence interval around the experimental dose-response surface was used to evaluate data statistically. Positive values or peaks above the horizontal plane at 0% inhibition were indicative of synergy; negative values or troughs in the plane indicated antagonism. These values are shown on the ordinate in Figures 1-3 .
Results

Individual effects of CDV and IUdR
Cytotoxicity of CDV and IUdR recorded MTC values of 1,000 µM and 100 µM, respectively. The compounds' effect on growing CEF resulted in a CGIC 50 value of 881µM and 17 µM for CDV, and IUdR, respectively. Evidently, IUdR had a stronger influence on the growth of CEF as compared with its effect on monolayer CEF cultures. These data are in accordance with the well known IUdRinduced block of eucaryotic cell proliferation in culture (Müller, 1979 The effect of CDV on VV replication is presented in Table 1 . As seen, CDV manifested approximately the same inhibitory effect against both virus strains tested. The antiviral activity of CDV was markedly dependent on the size of virus inoculum. For example, the IC 50 values towards the RIIPD strain varied between 8.5 µM at 10/100 virus ID 50 and 26.5 µM at 10,000 virus ID 50 ; whereas the IC 50 values of the Bratislava strain varied between 7.1 µM at 10/100 virus ID 50 and 13.6 µM at 10,000 virus ID 50 . The IC 50 values showed some strain differences for the stronger virus inocula: 26.5 µM and 21.3 µM for the RIIPD strain, and 13.6 µM and 17.5 µM for the Bratislava strain at 10,000 CCID 50 and 1,000 CCID 50 , respectively.
The SI values of CDV based on MTC ranged from 37.8-118.3 for the RIIIPD strain and 73.5-141.4 for the Bratislava strain. Very close SI ratios based on CGIC 50 were recorded: ranging from 33.3-124.6 for RIIPD strain and 50.2-124.6 for Bratislava strain.
It was discovered that both strains of VV possessed a similar susceptibility to the inhibitory effect of IUdR (Table 2) . Unlike CDV, the antiviral effect of IUdR was not dependent on virus inoculum size, for example, IC 50 values were within 0.7-0.85 µM for RIIIPD strain, and 0.58-0.7 µM for Bratislava strain.
A sharp difference was established in the IUdR antiviral selectivity measured in stationary CEF cultures and in growing cell cultures, based on the compound's stronger effect on growing cells. MTC/IC 50 values ranged between 117.7-142.9 and 140.9-172.4 for the RIIPD strain and the Bratislava strain, respectively, which were in contrast to the lower values of CGID 50 /IC 50 , ranging from 20.4-33.3.
Our results indicated that the individual antiviral effects of CDV and IUdR versus VV produced similar SI values when evaluating MTC/IC 50 , and were markedly higher for CDV at CGIC 50 /IC 50 .
Combination effect of CDV plus IUdR
Various combinations of CDV and IUdR were investigated to determine whether both compounds together enhanced the inhibitory effect on VV replication in vitro. The combination effect of CDV and IUdR versus VV replication in CEF culture was tested by following the Prichard and Shipman model (adapted to CPE inhibition test in 96-well microplates). Virus inoculum of 1,000 IC 50 had been selected and the compound concentrations were as follows: 64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25 µM for CDV, and 2, 1, 0.5, 0.25, 0.125, 0.062 and 0.031 µM for IUdR. Figure 1 shows the three-dimensional dose-response surface of the different combinations, based on the data from six independent experiments. As can be seen in the 95% confidence interval, the combination of CDV and IUdR leads to a well-manifested synergistic antiviral effect towards VV.
The combined effect of CDV and IUdR on the uninfected stationary monolayer and growing CEF cultures are presented on Figures 2 and 3 , respectively. In both tests, the combination of CDV and IUdR produced a lower cytotoxicity.
Discussion
Our results on the individual anti-VV effects of CDV and IUdR are comparable, or are very close, to those in other investigations using the CPE inhibition experimental design, in spite of certain differences in viral strains or cell cultures. For instance, in the case of IUdR, an EC 50 value of 1.13 µM was found versus the Copenhagen strain of VV grown in human embryonic lung cells (Neyts et al., 2002) , which is close to our EC 50 values of 0.58-0.85 µM. In the case of CDV, EC 50 values from previous reports record a wider range of values: 8.2 µM [Copenhagen strain in human embryonic lung cells (Neyts et al., 2002) ], 12.7 µM [Lederle strain in primary human keratinocytes (Snoeck et al., 2002) ], 10.1 and 13.4 µM [versus NYC and IHD strains, respectively, in human foreskin fibroblasts culture (Kern et al., 2002) ] and 32-46µM for Elstree, WR, Copenhagen and NYC strains in human foreskin fibroblasts (Kern et al., 2002; Keith et al., 2003) . Similar data were obtained by the plaque-reduction assay, when CDV was tested against Copenhagen strain in Vero 76 cells and produced an EC 50 value of 19 µM (Smee et al., 2002) . In our study, EC 50 values ranged from 7.1-26.5 µM and were strongly dependent on the virus inoculum size (Table 1) .
The synergistic character of the combination effect of CDV and IUdR on VV replication, and the reduced cytotoxicity, when applied to uninfected cells is based on their different mechanisms of action on cell and viral processes.
Literary data shows that the anti-poxvirus effect of CDV is shared by its intracellular active metabolite, CDVpp (formed by two consecutive phosphorylation steps catalysed by a pyrimidine nucleoside monophosphate and diphosphate kinases), which acts on the viral DNA polymerase activity and stops DNA chain elongation. It has been established (Evans et al., 2004) that VV DNA polymerase can use CDVpp as a substrate analogue of 2′-deoxycytidine 5′-triphosphate, thus incorporating CDV opposite a guanine nucleotide in the template strand.
IUdR affects several enzyme systems both in uninfected and DNA virus infected cells. It directly affects thymidine kinase; as IUdRp it affects thymidilate kinase, and as IUdRppp it affects DNA polymerase, thymidine kinase, deoxycytidylate deaminase and cytidine diphosphoreductase (Müller, 1979) with IUdRppp being incorporated into (viral/cellular) DNA. In VV infected cells, this leads to a particular inhibition of viral DNA synthesis including single and double-strand breaks (McCrea & Lipman, 1967; Prusoff & Goz, 1973) .
The synergistic nature of the CDV and IUdR combination effect on VV replication is probably due to IUdR's effect on the synthetic pathway of thymidine triphosphate and its incorporation in the DNA chain replacing deoxythymidine triphosphate, coupled with CDV simultaneously terminating DNA chain elongation.
In contrast to the synergism of combined CDV and IUdR observed in VV infected CEF culture, a reduced cytotoxicity is also observed in uninfected cells. This finding could be explained by the high anti-VV selectivity of the acyclic phosphonate CDV applied in the combination at completely non-toxic concentration for the cells. It has been proved that CDV does not exert significant effect on the cellular DNA synthesis. Thus, only IUdR affects the methabolic pathway of DNA in the intact cell. Evidently, the Prichard and Shipman (1990) method registers a lessened cytotoxicity for the combination.
Such simultaneously manifested combination effects; synergistic in the specific antiviral effect, but antagonistic in cytotoxicity could be considered as extremely favourable. Results of the present study show that the combination of CDV and IUdR might be significant for the development of more effective therapy against VV infections. 
